ATE290877T1 - Stabilisierte insulin-zubereitungen - Google Patents

Stabilisierte insulin-zubereitungen

Info

Publication number: ATE290877T1
Authority: AT; Austria
Prior art keywords: insulin preparations; stabilized insulin; glycylglycine; analogue; citrate
Prior art date: 1998-01-09

Application number

AT99900206T

Other languages

English (en)

Inventor

Peter Langballe

Elsebeth Norup

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-09

Filing date

1999-01-06

Publication date

2005-04-15

1999-01-06 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2005-04-15 Application granted granted Critical

2005-04-15 Publication of ATE290877T1 publication Critical patent/ATE290877T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
102000004877 Insulin Human genes 0.000 title abstract 2
108090001061 Insulin Proteins 0.000 title abstract 2
229940125396 insulin Drugs 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 abstract 4
108010008488 Glycylglycine Proteins 0.000 abstract 2
229940043257 glycylglycine Drugs 0.000 abstract 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
239000000872 buffer Substances 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
229910001424 calcium ion Inorganic materials 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
229910001425 magnesium ion Inorganic materials 0.000 abstract 1
229910021645 metal ion Inorganic materials 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99900206T 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen ATE290877T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98610001		1998-01-09
PCT/DK1999/000006 WO1999034821A1 (en)	1998-01-09	1999-01-06	Stabilised insulin compositions

Publications (1)

Publication Number	Publication Date
ATE290877T1 true ATE290877T1 (de)	2005-04-15

Family

ID=8235844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99900206T ATE290877T1 (de)	1998-01-09	1999-01-06	Stabilisierte insulin-zubereitungen

Country Status (7)

Country	Link
US (1)	US6174856B1 (de)
EP (1)	EP1044016B1 (de)
JP (1)	JP2002500196A (de)
AT (1)	ATE290877T1 (de)
AU (1)	AU1870099A (de)
DE (1)	DE69924232D1 (de)
WO (1)	WO1999034821A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR012894A1 (es)	1997-06-13	2000-11-22	Lilly Co Eli	Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
US20020155994A1 (en) *	1997-10-24	2002-10-24	Svend Havelund	Aggregates of human insulin derivatives
WO2000043034A2 (en) *	1999-01-26	2000-07-27	Eli Lilly And Company	Monodisperse hexameric acylated insulin analog formulations
US6734162B2 (en)	2000-01-24	2004-05-11	Minimed Inc.	Mixed buffer system for stabilizing polypeptide formulations
AUPQ633900A0 (en)	2000-03-20	2000-04-15	Jurox Pty Ltd	Anaesthetic composition
US20100129332A1 (en) *	2000-07-31	2010-05-27	Tamar Tennenbaum	Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) *	2002-07-09	2003-08-07	Tamar Tennenbaum	Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) *	2000-07-31	2006-11-16	Healor Ltd.	Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en)	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
CA2416788A1 (en) *	2000-07-31	2002-02-07	Tamar Tennenbaum	Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds
DE10114178A1 (de) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en)	2001-06-28	2004-05-18	Metronic Minimed, Inc.	Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20030158670A1 (en) *	2001-12-04	2003-08-21	Philip Hougaard	Method of planning and performing stability studies
AU2003208316A1 (en) *	2002-03-13	2003-09-22	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
WO2003094951A1 (en) *	2002-05-07	2003-11-20	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US20040126831A1 (en) *	2002-12-31	2004-07-01	Medtronic Minimed, Inc.	Functionalization of immobilized proteins
CA2531988C (en) *	2003-08-05	2016-06-28	Novo Nordisk A/S	Novel insulin derivatives
WO2005013885A2 (en)	2003-08-07	2005-02-17	Healor Ltd.	Pharmaceutical compositions and methods for accelerating wound healing
RU2527893C2 (ru) *	2004-07-19	2014-09-10	Биокон Лимитед	Инсулин-олигомерные конъюгаты, их препараты и применения
US8263551B2 (en)	2004-11-22	2012-09-11	Novo Nordisk A/S	Soluble, stable insulin-containing formulations with a protamine salt
EP2256130B1 (de)	2005-02-02	2013-09-25	Novo Nordisk A/S	Neuartige Insulinderivate
EP2452686A3 (de)	2005-08-29	2012-09-05	HealOr Ltd.	Verfahren und Zusammensetzungen zur Vorbeugung und Behandlung von diabetischer und alternder Haut
ES2371361T3 (es) *	2005-12-28	2011-12-30	Novo Nordisk A/S	Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DE602007009496D1 (de) *	2006-02-27	2010-11-11	Novo Nordisk As	Insulinderivate
EP2015770B1 (de) *	2006-05-09	2012-09-26	Novo Nordisk A/S	Insulinderivate
WO2007128815A1 (en) *	2006-05-09	2007-11-15	Novo Nordisk A/S	Insulin derivative
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
CN102755649A (zh) *	2007-07-30	2012-10-31	希尔洛有限公司	药物组合物及相关方法
RU2453332C2 (ru) *	2007-10-16	2012-06-20	Байокон Лимитид	Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
EP2217621B1 (de) *	2007-11-08	2015-04-22	Novo Nordisk A/S	Insulinderivat
MY152979A (en)	2008-01-09	2014-12-15	Sanofi Aventis Deutschland	Novel insulin derivatives having an extremely delayed time-action profile
EP2113564A1 (de) *	2008-05-01	2009-11-04	Arecor Limited	Proteinformulierung
TWI451876B (zh) *	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
FR2932908B1 (fr) *	2008-06-24	2012-11-16	Arjowiggins Licensing Sas	Structure comportant un filigrane ou pseudo-filigrane et un dispositif a microcircuit integre.
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
JP4959005B2 (ja) *	2008-10-30	2012-06-20	ノボ・ノルデイスク・エー／エス	毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
WO2010088286A1 (en)	2009-01-28	2010-08-05	Smartcells, Inc.	Synthetic conjugates and uses thereof
BRPI1007457A2 (pt)	2009-01-28	2015-08-25	Smartcells Inc	Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
US8623345B2 (en)	2009-03-20	2014-01-07	Smartcells	Terminally-functionalized conjugates and uses thereof
US9018190B2 (en)	2009-03-27	2015-04-28	Adocia	Functionalized oligosaccharides
FR2943538B1 (fr)	2009-03-27	2011-05-20	Adocia	Formulation a action rapide d'insuline recombinante humaine
CN102596175A (zh) *	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
US20110097363A1 (en) *	2009-10-22	2011-04-28	Cpex Pharmaceuticals, Inc.	Therapeutically Effective Preparations of Insulin
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
EP2523677A2 (de)	2010-01-11	2012-11-21	Healor Ltd.	Verfahren zur behandlung von entzündungskrankheiten und -erkrankungen
CA2805031A1 (en) *	2010-07-07	2012-01-12	Biodel, Inc.	Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130231281A1 (en)	2011-11-02	2013-09-05	Adocia	Rapid acting insulin formulation comprising an oligosaccharide
WO2014096985A2 (en)	2012-12-19	2014-06-26	Wockhardt Limited	A stable aqueous composition comprising human insulin or an analogue or derivative thereof
US9381247B2 (en) *	2012-04-16	2016-07-05	Biodel Inc.	Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
CN104902922B (zh)	2012-11-13	2017-12-12	阿道恰公司	包含经取代阴离子化合物的速效胰岛素制剂
US9707276B2 (en)	2012-12-03	2017-07-18	Merck Sharp & Dohme Corp.	O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
MX2015006997A (es)	2012-12-26	2015-09-23	Wockhardt Ltd	Composicion farmaceutica.
EP2991672A1 (de)	2013-04-30	2016-03-09	Novo Nordisk A/S	Neuartiges verabreichungsschema
AR099569A1 (es)	2014-02-28	2016-08-03	Novo Nordisk As	Derivados de insulina y los usos médicos de estos
US9795678B2 (en)	2014-05-14	2017-10-24	Adocia	Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr)	2014-05-14	2018-08-31	Adocia	Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TW201630622A (zh)	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
BR112017018060A2 (pt) *	2015-02-25	2018-04-10	Dance Biopharm Inc	formulação de insulina, dose de unidade, e, método de tratar um indivíduo com diabetes melito.
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
JO3749B1 (ar) *	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr)	2015-11-16	2019-05-31	Adocia	Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
JP2019529506A (ja)	2016-09-29	2019-10-17	アレコルリミテッド	新規の製剤
CN110662551B (zh)	2017-06-01	2023-07-18	伊莱利利公司	速效胰岛素组合物
EP3727424A4 (de)	2017-12-18	2021-10-27	Merck Sharp & Dohme Corp.	Konjugatbasierte systeme für kontrollierte insulinfreisetzung
US11413352B2 (en)	2017-12-18	2022-08-16	Merck, Sharp & Dohme LLC	Conjugate based systems for controlled insulin delivery
US12357562B2 (en)	2018-04-04	2025-07-15	Arecor Limited	Injection pen system for the delivery of an insulin compound
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
GB2610490A (en)	2020-03-31	2023-03-08	Protomer Tech Inc	Conjugates for selective responsiveness to vicinal diols
IL302775A (en)	2020-11-19	2023-07-01	Protomer Tech Inc	Aromatic boron-containing compounds and insulin analogs
US20230025595A1 (en) *	2021-07-13	2023-01-26	America Great Health, a California Corporation	Formulation and Method of Preparing Divalent Cation Charged Insulin for Oral Administration
IL317049A (en)	2022-05-18	2025-01-01	Protomer Tech Inc	Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU550068B2 (en) *	1981-03-10	1986-02-27	Novo Nordisk A/S	Zinc insulin stabilized with calcium or magnesium salts
PH23446A (en) *	1986-10-20	1989-08-07	Novo Industri As	Peptide preparations
JP2628340B2 (ja) *	1988-05-14	1997-07-09	株式会社いかがく	血液中のインシュリン成分の安定方法
DE3827533A1 (de) *	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus
JP2837956B2 (ja) *	1993-06-21	1998-12-16	ノボノルディスクアクティーゼルスカブ	Ａｓｐ▲上Ｂ２８▼インスリン結晶
EP1132404A3 (de) *	1993-09-17	2002-03-27	Novo Nordisk A/S	Acyliertes Insulin
JP3414539B2 (ja) *	1994-05-11	2003-06-09	有限会社ドット	経鼻吸収用組成物
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
BR9709845B1 (pt) *	1996-06-20	2008-11-18		preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.

1999
- 1999-01-06 WO PCT/DK1999/000006 patent/WO1999034821A1/en not_active Ceased
- 1999-01-06 JP JP2000527269A patent/JP2002500196A/ja active Pending
- 1999-01-06 AT AT99900206T patent/ATE290877T1/de not_active IP Right Cessation
- 1999-01-06 DE DE69924232T patent/DE69924232D1/de not_active Expired - Lifetime
- 1999-01-06 EP EP99900206A patent/EP1044016B1/de not_active Expired - Lifetime
- 1999-01-06 AU AU18700/99A patent/AU1870099A/en not_active Abandoned
- 1999-01-07 US US09/227,053 patent/US6174856B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU1870099A (en)	1999-07-26
EP1044016A1 (de)	2000-10-18
JP2002500196A (ja)	2002-01-08
DE69924232D1 (de)	2005-04-21
EP1044016B1 (de)	2005-03-16
WO1999034821A1 (en)	1999-07-15
US6174856B1 (en)	2001-01-16

Legal Events

Date	Code	Title	Description
2005-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE290877T1 (de)	2005-04-15	Stabilisierte insulin-zubereitungen
DK1175149T3 (da)	2003-03-17	Desinficerende sammensætning baseret på H2O2, syrer og metaliioner
BR0112969A (pt)	2004-06-22	Método de utilização de dicetopiperazinas e composições contendo-as
DK1082109T3 (da)	2004-08-09	Oral formulering omfattende biguanid og en organisk syre
BR0107811B1 (pt)	2013-03-05	composiÇço herbicida seletiva e mÉtodos de controle de plantas.
IL127366A0 (en)	1999-10-28	Insulin preparations containing NaCl
ATE310531T1 (de)	2005-12-15	Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung
NO20012994L (no)	2002-12-16	Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesieltdataobjekter i MMS-meldinger
NO20015471D0 (no)	2001-11-08	Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
DE69927795D1 (en)	2006-03-02	Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
NO20031860L (no)	2003-06-30	Kahalalid F
MXPA03010684A (es)	2005-11-04	Peptidos y el uso de los mismos para oscurecer la piel.
BRPI0209619B8 (pt)	2021-05-25	agente promotor de crescimento capilar
DK1178726T3 (da)	2003-06-10	Vandig opløsning til konservering af væv og organer
AU2001269575A1 (en)	2002-03-22	Nucleic acid sequences and proteins involved in cellular senescence
NO20024760D0 (no)	2002-10-03	Stabil og effektiv myk, fast antiperspirant og/eller deodorant
MY128230A (en)	2007-01-31	Antifungal composition
MXPA03002875A (es)	2003-07-14	Composicion de vacuna y metodo de estabilizacion.
MY138219A (en)	2009-05-29	Biologically active peptides
BR0317119A (pt)	2005-10-25	Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
ATE238050T1 (de)	2003-05-15	4-cyano-4-deformylsordarizin-derivate
WO2002066513A3 (de)	2003-04-03	Humane zirkulierende lekti fragmente hf7072, hf7638 und hf14448 sowie ihre verwendung
DE69602208D1 (de)	1999-05-27	Stabilisierte pharmazeutische zusammensetzungen enthaltend dobutamine
ATE241979T1 (de)	2003-06-15	4-cyano-4-deformylsordarinderivate
SE9502927D0 (sv)	1995-08-24	Solution containing IGF-I